ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0388

Incidence Rate and Factors Associated with Fractures Among Older Adults with Ankylosing Spondylitis in the United States

Rachael Stovall1, Emma Kersey1, Jing Li2, Rahaf Baker3, Christine Anastasiou2, Gabriela Schmajuk4, Lianne Gensler5 and Jinoos Yazdany6, 1University of California San Francisco, San Francisco, CA, 2University of California, San Francisco, San Francisco, CA, 3Alameda Highland Internal Medicine Residency, Oakland, CA, 4UCSF / SFVA, San Francisco, CA, 5Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, 6UCSF, San Francisco, CA

Meeting: ACR Convergence 2022

Keywords: Ankylosing spondylitis (AS), Fracture

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Adults with ankylosing spondylitis (AS) are at a significantly increased risk of fracture relative to the general population. While some studies have evaluated the risk of fracture in AS, we do not have any U.S. population-level studies assessing all fracture types performed within the last three decades. We evaluated the incidence rate and factors associated with fractures among those with AS using linked data from the Rheumatology Informatics System for Effectiveness (RISE) registry and Medicare claims.

Methods: Data were derived from RISE, a large, national electronic health record-based registry, which was linked to Medicare claims from 2016-2018. Patients were required to have at least two visits for AS with a rheumatology provider, ≥ 30 days apart, prior to the baseline period of the study (Figure). Then, they were required to have at least one Medicare claim. Once this was confirmed, we collected one year of baseline characteristics from both RISE and Medicare claims. Patients with a fracture prior to the index date were excluded. Starting at the index date, patients were followed over time for fractures. Fractures were defined by ICD codes. We examined any fracture including those of the vertebra (cervical, thoracic, lumbar, sacral, and coccygeal), clavicle, ribs, sternum, humerus, ulna, distal radius, wrist, pelvis, hip, femur, knee, tibia, fibula, ankle, and foot. First, we calculated the incidence rate of fractures among individuals with AS. Second, logistic regression models were constructed to identify factors associated with fracture, including age, sex, race or ethnic group, body mass index (BMI), dual-eligibility for Medicare and Medicaid, area deprivation index, Charlson comorbidity index, smoking status, diagnosis of osteoporosis, and use of osteoporosis treatment, glucocorticoids, and opioids.

Results: We identified 2,092 adults with AS in RISE who were also observable in Medicare. The mean (SD) age was 68.4 years (10.1), 43.7% were female, and 75.7% were non-Hispanic White (Table). Ten percent had dual-eligibility for Medicare and Medicaid. Fractures occurred in 137 AS adults. The overall incidence rate of fractures among adults with AS was 37.01 (95% CI 31.31-43.76) per 1,000 person-years. Older age (OR 2.70, 95% CI 1.14 – 6.42), BMI < 18.5 (OR 5.47, 95% CI 1.85 – 16.20), higher Charlson comorbidity index (OR 1.83, 95% CI 1.22 – 2.75), osteoporosis diagnosis (OR 2.33, 95% CI 1.53 – 3.55), and chronic use of opioid drugs (OR 1.77, 95% CI 1.17 – 2.67) conferred increased odds of fracture.

Conclusion: In this large U.S. sample of older adults with AS, those who were older, had a low BMI, had multiple comorbidities including osteoporosis, and used opioids chronically had a higher odds of fracture. Men and women with AS were equally likely to have a fracture, unlike in the general population where women are known to be at higher risk. Because chronic opioid use was associated with fracture in AS, this high-risk population should be considered for interventions to mitigate risk.

Disclaimer: Data collection was supported by the ACR’s RISE Registry. The views expressed represent those of the authors, not necessarily those of ACR.

Supporting image 1

Supporting image 2


Disclosures: R. Stovall, None; E. Kersey, None; J. Li, None; R. Baker, None; C. Anastasiou, None; G. Schmajuk, None; L. Gensler, Novartis, Pfizer Inc, UCB Pharma, AbbVie, Eli Lilly, Janssen, Gilead, Moonlake; J. Yazdany, AstraZeneca, Gilead, Bristol-Myers Squibb(BMS), Aurinia, Astra Zeneca, Pfizer.

To cite this abstract in AMA style:

Stovall R, Kersey E, Li J, Baker R, Anastasiou C, Schmajuk G, Gensler L, Yazdany J. Incidence Rate and Factors Associated with Fractures Among Older Adults with Ankylosing Spondylitis in the United States [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/incidence-rate-and-factors-associated-with-fractures-among-older-adults-with-ankylosing-spondylitis-in-the-united-states/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-rate-and-factors-associated-with-fractures-among-older-adults-with-ankylosing-spondylitis-in-the-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology